{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:fondaparinux",
  "owner": "cardio",
  "kind": "drug",
  "slug": "fondaparinux",
  "name": "Fondaparinux",
  "aliases": [
    "Arixtra",
    "Fondaparinux sodium"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Fondaparinux, sold as Arixtra, is an anticoagulant of the Factor Xa inhibitor type, given by injection under the skin. The US label read lists, in adults, prophylaxis of deep vein thrombosis in people having hip fracture, hip replacement, knee replacement or abdominal surgery, and treatment of acute deep vein thrombosis or acute pulmonary embolism when given with warfarin sodium. It also lists treatment of venous thromboembolism in children aged 1 year or older who weigh at least 10 kg. The label carries a boxed warning about epidural or spinal hematomas in people who are anticoagulated and have neuraxial anesthesia or a spinal puncture.",
  "summary_technical": "RxNorm ingredient 321208; UNII X0Q6N9USOZ is the UNII of fondaparinux sodium, the form the label names, and is a broad match. MeSH descriptor D000077425 is Fondaparinux. Class: Factor Xa Inhibitor (FDA established pharmacologic class, RxClass); the label also writes (anticoagulant) after the class name. The label read is the Mylan Institutional LLC label for Arixtra, application NDA021345, effective 2024-12-10 in openFDA. Adult and paediatric statements are kept in separate contexts and claims. This page records label indications, the first sentence of the boxed warning and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-09",
  "last_evidence_check": "2026-11-09",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "321208",
      "normalized_value": "321208",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "X0Q6N9USOZ",
      "normalized_value": "X0Q6N9USOZ",
      "match": "broad",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D000077425",
      "normalized_value": "D000077425",
      "match": "exact",
      "version": "read 2026-11-09",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says fondaparinux, through antithrombin III, selectively inhibits Factor Xa, which interrupts the blood coagulation cascade."
  },
  "content_digest": "18bb54ee39999d7b46238c5b0a04418e7ee8fd56fc78729e38a295662f0e2d15",
  "review": {
    "content_digest": "18bb54ee39999d7b46238c5b0a04418e7ee8fd56fc78729e38a295662f0e2d15",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-fondaparinux-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:fondaparinux",
      "category": "descriptive",
      "statement": "The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.",
      "context": {
        "id": "cardio:ctx-fda-fondaparinux-label-us",
        "label": "Adults for whom the US label of fondaparinux (Arixtra) lists an indication: prophylaxis of deep vein thrombosis after hip fracture, hip replacement, knee replacement or abdominal surgery; treatment of deep vein thrombosis or acute pulmonary embolism",
        "recipient": "adult",
        "population": "Adult patients described in the indications sections of the label.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the passages read state",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adult patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, for prophylaxis of deep vein thrombosis",
            "Adult patients with deep vein thrombosis or acute pulmonary embolism, when administered in conjunction with warfarin sodium"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-09",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, first bullet",
          "applicability_note": "Label passage quoted in the research quote table (LB-05).",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second bullet",
          "applicability_note": "Label passage quoted in the research quote table (LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], sentence 1",
          "applicability_note": "Label passage quoted in the research quote table (LB-08).",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241210.",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "324be1ff52cd9425a72958df4e38c9ae52b80ac6799b0166dcef8a56a47bcacc",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-fondaparinux-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-fondaparinux-label-paediatric",
      "owner": "cardio",
      "subject_entity_id": "cardio:fondaparinux",
      "category": "descriptive",
      "statement": "The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.",
      "context": {
        "id": "cardio:ctx-fda-fondaparinux-label-paediatric",
        "label": "Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg",
        "recipient": "child",
        "population": "Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Children aged 1 year or older, as the passage read states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Pediatric patients aged 1 year or older weighing at least 10 kg, with venous thromboembolism"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-09",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.4 Treatment of Venous Thromboembolism in Pediatric Patients",
          "applicability_note": "Label passage quoted in the research quote table (LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20241210.",
          "snapshot": {
            "id": "cardio:openfda-label-arixtra-2026-11-09",
            "retrieved_at": "2026-11-09T13:16:13Z",
            "content_hash": "1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9",
            "source_effective_date": "2024-12-10",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-arixtra",
            "source_type": "regulator",
            "title": "openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/wb25-openfda-label-fondaparinux.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "4a8b14cbe7e9ecb64eeaf0f1c9685f23e1d964474ffee82aed947b259d1e97d9",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-fondaparinux-label-paediatric.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "The label describes fondaparinux as a Factor Xa inhibitor (anticoagulant); RxClass lists the Factor Xa Inhibitor pharmacologic class",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:anticoagulants",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-arixtra-2026-11-09",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists prophylaxis and treatment of deep vein thrombosis in adults as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:deep-vein-thrombosis",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-fondaparinux-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists treatment of acute pulmonary embolism in adults, with warfarin sodium, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-embolism",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-fondaparinux-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "core:venous-thromboembolism",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-fondaparinux-label-paediatric",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "related_to",
        "label": "Related to",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:superficial-vein-thrombosis",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "contains",
        "label": "Contained in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:fdaprod-nda021345",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ofeed-nda021345-2024-12-23",
          "locator": "products[0].active_ingredients[0].name"
        },
        "primary": false,
        "role": "active",
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/fondaparinux/",
  "context_path": "api/v1/context/cardio--fondaparinux.md"
}
